MarketCap
Facebook
X
Telegram
Nkarta Accounts Payables | NKTX
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Nkarta
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.09 M | 638 K | 3.66 M | 1.76 M | 1.11 M | 1.18 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.66 M | 638 K | 1.74 M |
Quarterly Accounts Payables Nkarta
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.09 M | 1.59 M | 638 K | 1.44 M | 1.51 M | 1.49 M | 3.66 M | 1.94 M | 3.76 M | 3.18 M | 1.76 M | 4.28 M | 3.01 M | 5.41 M | 1.76 M | 9.49 M | 2.97 M | 2.02 M | 1.11 M | 2.14 M | 2.16 M | 2.01 M | 1.18 M | 1.18 M | 1.18 M | - | 1.88 M | 1.88 M | 1.88 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.49 M | 638 K | 2.45 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
1.39 M | - | -6.63 % | $ 13.9 M |  USA |
 |
Synthetic Biologics
SYN
|
1.01 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
9.06 M | - | - | $ 2.02 B | USA |
 |
I-Mab
IMAB
|
427 M | - | - | $ 866 M |  China |
 |
AgeX Therapeutics
AGE
|
1.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
Qilian International Holding Group Limited
QLI
|
6.56 M | - | -6.08 % | $ 184 M | China |
 |
Happiness Biotech Group Limited
HAPP
|
1.43 M | - | 1.35 % | $ 17.8 M | China |
 |
Athira Pharma
ATHA
|
4.59 M | - | - | $ 269 M | USA |
|
Galera Therapeutics
GRTX
|
265 K | - | -32.59 % | $ 7.61 M | USA |
 |
Hepion Pharmaceuticals
HEPA
|
168 K | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
4.16 M | - | 1052.0 % | $ 415 M | USA |
 |
Codexis
CDXS
|
1.55 M | $ 1.46 | 2.82 % | $ 127 M | USA |
 |
Ardelyx
ARDX
|
19.2 M | $ 3.78 | 1.89 % | $ 911 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
12.5 M | $ 23.9 | 1.01 % | $ 3.04 B | USA |
 |
Assembly Biosciences
ASMB
|
1.17 M | $ 36.6 | 1.3 % | $ 410 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
2.11 M | - | -1.58 % | $ 28.1 M | China |
 |
Adial Pharmaceuticals
ADIL
|
655 K | $ 7.12 | 6.91 % | $ 4.76 M | USA |
 |
Generation Bio Co.
GBIO
|
1.41 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
617 K | - | -4.36 % | $ 27 M | USA |
 |
Axsome Therapeutics
AXSM
|
65.5 M | $ 206.68 | 0.16 % | $ 10.3 B | USA |
 |
GlycoMimetics
GLYC
|
329 K | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
3.87 M | $ 56.8 | 0.94 % | $ 1.63 B | USA |
 |
AVROBIO
AVRO
|
1.09 M | - | 1083.1 % | $ 745 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
32.8 M | $ 66.53 | 0.15 % | $ 12.8 B | USA |
 |
BeiGene, Ltd.
BGNE
|
479 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AIkido Pharma
AIKI
|
611 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
896 K | - | - | $ 1.01 B | USA |
 |
Aptose Biosciences
APTO
|
2.91 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Bicycle Therapeutics plc
BCYC
|
9.67 M | $ 4.3 | 1.42 % | $ 298 M |  Britain |
 |
AlloVir
ALVR
|
1.28 M | - | 4.14 % | $ 49.1 M | USA |
 |
ChromaDex Corporation
CDXC
|
10.8 M | - | -0.88 % | $ 598 M | USA |